Ibrutinib discontinuation in Waldenström macroglobulinemia: Etiologies, outcomes, and IgM rebound
Joshua Gustine(Boston University), Jorge J. Castillo(Dana-Farber Cancer Institute), Kirsten Meid(Shaanxi Research Association for Women and Family), Patricia Severns(Harvard University), Steven P. Treon(Dana-Farber Cancer Institute), Toni Dubeau(Shaanxi Research Association for Women and Family), Guang Yang(Blueprint Medicines (United States)), Lian Xu(Huazhong Agricultural University), Zachary R. Hunter(Harvard University)
Cited by 73
Related Papers
The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee
|Blood|2022|1.5k
Thalidomide and immunomodulatory derivatives augment natural killer cell cytotoxicity in multiple myeloma
|Blood|2001|905
Immunopathology of Hyperinflammation in COVID-19
|American Journal Of Pathology|2020|526
Infectious Complications Associated with Alemtuzumab Use for Lymphoproliferative Disorders
|Clinical Infectious Diseases|2006|270
Ibrutinib Monotherapy in Symptomatic, Treatment-Naïve Patients With Waldenström Macroglobulinemia
|Journal of Clinical Oncology|2018|176